drug_type
RELEVANT_DRUG
intervention_type
Cellular gene therapy (CAR T cells)
drug_description
An autologous anti-CD19 CAR-T cell therapy generated by leukapheresis of patient T cells, CD3/CD28 activation, and lentiviral transduction to express a CD19-specific chimeric antigen receptor; administered after lymphodepleting chemotherapy to target CD19+ B-cell malignancies. Mechanism: CAR binding to CD19 triggers T-cell activation and cytotoxicity, leading to elimination of CD19-positive cells and on-target B-cell aplasia.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are lentivirally transduced to express a CD19-specific chimeric antigen receptor; CAR engagement of CD19 on B cells triggers T-cell activation, proliferation, cytokine release, and perforin/granzyme-mediated cytotoxicity, eliminating CD19-positive malignant cells and causing on-target B-cell aplasia.
drug_name
CUCART19
nct_id_drug_ref
NCT06462248